The Evolving Role of Lutetium-PSMA in the Era of Personalized Medicine - Michael Hofman

March 30, 2020

Carmel Pezaro and Michael Hofman discuss the evolving role of lutetium-PSMA in the highly personalized treatment strategy for metastatic castrate-resistant prostate cancer in the era of personalized medicine.   Michael Hofman discusses the research on 177Lu-DOTA-PSMA-617 (177Lu-PSMA-617), a PSMA-targeted small molecule with favorable properties and is the most extensively investigated PSMA radioligand for radionuclide therapy (RNT) in PC. He shares the data that supports patient selection and discusses the rationale for the use of FDG PET and PSMA PET/CT as essential tools in the decision process for treatment. 


Michael S. Hofman, MD, Ph.D., FRACP, FAANMS, Professor of Molecular Imaging, The University of Melbourne, and Nuclear Medicine Physician in the Centre for Cancer Imaging at the Peter MacCallum Cancer Centre in Melbourne, Australia. Professor Michael Hofman is a nuclear medicine physician and physician-scientist. He previously completed a research fellowship at Guy's & St Thomas' in London and had consultant appointments in the private sector. He has a broad interest in positron emission tomography (PET), molecular imaging applications in oncology and radionuclide therapy, with a particular interest in novel PET radiotracers and theranostics. His research has pioneered the use of Ga-68 PET in a number of domains including pulmonary (ventilation/perfusion), renal imaging, and oncologic imaging of endocrine and prostate tumors. He has strong expertise in all aspects of theranostics including prostate and neuroendocrine cancers.

Carmel Pezaro, BHB MBChB, FRACP, DMedSc, MHPE.  Yorkshire Cancer Research (YCR) Senior Clinical Research Fellow.  Dr. Pezaro is a medical oncologist and researcher, with an interest in prostate cancer. Following oncology training and a doctoral degree in urothelial cancer, she spent two years working in the Prostate Cancer Targeted Therapy Group at The Institute of Cancer Research / Royal Marsden.  From 2013 until 2018 I worked as a medical oncologist at Eastern Health and Monash University in Melbourne, where she participated in laboratory and clinical research programs. She was the deputy chair of the Australian and New Zealand Urogenital and Prostate trials group (ANZUP) prostate cancer subcommittee and was actively involved in collaborative and industry trials. Her research output includes 70 publications since 2008 and both chief and co-investigator grant funding. As a complement to her academic research interest, she undertook a Master of Health Professional Education, which I completed in mid-2018.  In October 2018 she moved to Sheffield to commence a 5-year clinical research fellowship with Yorkshire Cancer Research, alongside clinical duties.

Read the Full Video Transcript

email news signup